Objective: This study was undertaken to learn about the involvement of optometrists in the eye care of diabetic patients in New York and to collect baseline data for planning intervention programs in diabetic eye disease.
Research Design And Methods: This study was conducted by a mail survey being sent to all optometrists in New York whom we could identify through state sources (n = 2270). Three follow-up mailings were conducted.
Results: Eighty-six percent who received our mailing responded, 87% of whom reported that they see diabetic patients. Analysis was confined to this 87%. Routine retinal examinations were provided by 68% of the respondents who see diabetic patients, 62% of whom dilate the pupils. Sixty-eight percent who see diabetic patients diagnose retinopathy solely by their own examination, and 60% of these dilate. Follow-up of retinopathy was provided by 15% of optometrists who see diabetic patients, 90% of whom dilate the pupils of their diabetic patients. Twenty-five percent of respondents who see diabetic patients refer them to an ophthalmologist for diagnosis of retinopathy, and 67% refer all retinopathy patients to an ophthalmologist for follow-up. Although 91% of respondents recommended eye examinations at least annually for diabetic patients, only 68% specifically recommended annual examinations through dilated pupils. Those who dilate were significantly more likely to recommend annual dilated examinations than those who do not dilate, regardless of practice setting.
Conclusions: These findings indicate that optometrists as a group see many diabetic patients. Intervention strategies should include increased emphasis on the use of dilation when examining diabetic patients and annual dilated retinal examinations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2337/diacare.14.1.34 | DOI Listing |
Viruses
December 2024
Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy.
Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection through antiviral regimes. Currently, highly effective direct-acting antivirals (DAAs) offer extraordinary success across all patient categories, including cirrhotics.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Urology Department, Hospital de Santa Maria, 1649-028 Lisbon, Portugal.
Background/objectives: Urinary tract infections (UTI) represent a highly frequent and debilitating disease. Immunoactive prophylaxis, such as the polyvalent bacterial whole-cell-based sublingual vaccine MV140, have been developed to avoid antibiotic use. However, the effectiveness of this tool in the Portuguese population is still unknown.
View Article and Find Full Text PDFSensors (Basel)
December 2024
Internal Medicine, Kanai Hospital, 612-12, Yodokizu-cho, Fushimi-ku, Kyoto 613-0911, Japan.
Diabetes is known to reduce blood circulation in capillaries and arterioles; however, no devices can easily measure this on a daily basis. In this study, we developed a tool for measuring finger photoplethysmograms using green light and near-infrared LEDs. Thereafter, photoplethysmography was conducted on 25 inpatients/outpatients with diabetes and 21 adult males and females who had not been diagnosed with or treated for diabetes, hypertension, or cardiovascular disease (control group).
View Article and Find Full Text PDFPharmaceutics
December 2024
Department of Physico-Chemistry, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universității Street, 700115 Iasi, Romania.
Diabetes is a growing global health crisis that requires effective therapeutic strategies to optimize treatment outcomes. This study aims to address this challenge by developing and characterizing extended-release polymeric matrix tablets containing metformin hydrochloride (M-HCl), a first-line treatment for type 2 diabetes, and honokiol (HNK), a bioactive compound with potential therapeutic benefits. The objective is to enhance glycemic control and overall therapeutic outcomes through an innovative dual-drug delivery system.
View Article and Find Full Text PDFPharmaceutics
December 2024
Department of Obstetrics and Gynecology, Grigore T. Popa University of Medicine and Pharmacy, 700111 Iasi, Romania.
Diabetes is a widespread metabolic illness. Mismanagement of diabetes can lead to severe complications that tremendously impact patients' quality of life. The assimilation of nanotechnology in diabetes care holds the potential to revolutionize treatment paradigms, improve patient outcomes, and reduce the economic burden associated with this pervasive disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!